Endocrine aging shapes immune-skeletal vulnerability in osteoporosis: an evidence-weighted framework

Skeletal deterioration in later life reflects endocrine transitions alongside changes in immune activity, hematopoiesis and the bone marrow environment. These processes are often considered together, although the evidence linking them to human fracture outcomes is uneven. We critically examine sex-steroid decline, vitamin D signaling, exogenous glucocorticoids and metabolic hormones in relation to immune-cell remodeling, marrow niche dysfunction and bone remodeling. Evidence was appraised qualitatively at the level of specific claims, distinguishing established human skeletal effects from observational associations, experimental mechanisms and early hypotheses. The clearest clinical evidence concerns postmenopausal estrogen deficiency, glucocorticoid-induced bone loss and receptor activator of nuclear factor-κB ligand (RANKL)-dependent osteoclastogenesis. By contrast, the contribution of particular T-cell cytokine routes, vitamin D-mediated immune polarization, NOD-like receptor family pyrin domain-containing 3 (NLRP3), cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) and senescence-associated secretory programs to common human osteoporosis remains difficult to establish. Randomized trial findings also challenge straightforward translation of plausible pathways: vitamin D supplementation did not reduce fractures in an unselected population, and an exploratory senolytic intervention did not improve its prespecified bone resorption endpoint overall. Bone marrow adiposity and inflammatory biomarkers add further complexity because their meaning varies with tissue location, comorbidity and time. We discuss five overlapping research profiles and the prospective evidence needed to determine whether endocrine–immune measurements improve skeletal prediction or treatment selection beyond established clinical assessment.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-18
DOI
https://doi.org/10.3389/fendo.2026.1976601
Primary Topic
Bone health and osteoporosis research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Endocrine aging shapes immune-skeletal vulnerability in osteoporosis: an evidence-weighted framework

尚东雨, 徐西林, Yu Han, Zixuan Wu et al.
Frontiers in Endocrinology
Bone health and osteoporosis research
article

Endocrine aging shapes immune-skeletal vulnerability in osteoporosis: an evidence-weighted framework

尚东雨, 徐西林, Yu Han, Zixuan Wu, Kai Sun, Xiaodong Li, Zhi Chen
article en

Abstract

Skeletal deterioration in later life reflects endocrine transitions alongside changes in immune activity, hematopoiesis and the bone marrow environment. These processes are often considered together, although the evidence linking them to human fracture outcomes is uneven. We critically examine sex-steroid decline, vitamin D signaling, exogenous glucocorticoids and metabolic hormones in relation to immune-cell remodeling, marrow niche dysfunction and bone remodeling. Evidence was appraised qualitatively at the level of specific claims, distinguishing established human skeletal effects from observational associations, experimental mechanisms and early hypotheses. The clearest clinical evidence concerns postmenopausal estrogen deficiency, glucocorticoid-induced bone loss and receptor activator of nuclear factor-κB ligand (RANKL)-dependent osteoclastogenesis. By contrast, the contribution of particular T-cell cytokine routes, vitamin D-mediated immune polarization, NOD-like receptor family pyrin domain-containing 3 (NLRP3), cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) and senescence-associated secretory programs to common human osteoporosis remains difficult to establish. Randomized trial findings also challenge straightforward translation of plausible pathways: vitamin D supplementation did not reduce fractures in an unselected population, and an exploratory senolytic intervention did not improve its prespecified bone resorption endpoint overall. Bone marrow adiposity and inflammatory biomarkers add further complexity because their meaning varies with tissue location, comorbidity and time. We discuss five overlapping research profiles and the prospective evidence needed to determine whether endocrine–immune measurements improve skeletal prediction or treatment selection beyond established clinical assessment.

Frontiers in EndocrinologyVol. 17
Heilongjiang University of Chinese Medicine (CN), First Affiliated Hospital of Heilongjiang University of Chinese Medicine (CN), Heilongjiang Provincial Hospital (CN), Heilongjiang University (CN)
Health Commission of Heilongjiang Province
Good health and well-being
Bone health and osteoporosis research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon